ResearchSafe

Cagrilintide (Cagrilintide (AM833))

Category: Weight Management. Status: Investigational (Phase III).

A long-acting amylin analog being investigated for obesity, both on its own and in a fixed-ratio combination with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying.

How it works

Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1.

Key facts

  • Molecular weight: ~3963 Da
  • Half-life: ~7-8 days
  • Bioavailability: High via subcutaneous injection
  • Storage: Lyophilized: refrigerate. Reconstituted: 2-8°C, use within ~30 days.

Dosing overview

  • Typical dose: 0.3-2.4 mg (titrated)
  • Frequency: Once weekly
  • Duration: Ongoing while needed
  • Route: Subcutaneous injection

Protocol notes

  • Trials titrate slowly from a low dose (e.g. ~0.3 mg) upward over several weeks to limit nausea.
  • Once-weekly dosing is enabled by the long half-life; a fixed weekday is typical.
  • Often studied alongside semaglutide (CagriSema) to combine amylin and GLP-1 satiety pathways.

Reported benefits

  • Appetite suppression and increased satiety
  • Meaningful weight loss
  • Complements GLP-1 agonists (additive effect)
  • Slows gastric emptying

Possible side effects

  • Nausea (dose-dependent)
  • Reduced appetite
  • Injection site reactions
  • Constipation or GI upset

Research

  • Cagrilintide once weekly for weight management (2021): Phase 2 trial showed dose-dependent weight loss up to ~10.8% at 26 weeks vs ~3% placebo.
  • CagriSema (cagrilintide + semaglutide) in obesity (2023): Combination achieved roughly 15-17% weight loss, exceeding either agent alone.

Compare Cagrilintide

Community discussions about Cagrilintide

Research and educational reference only. Not medical advice.